Answers are grounded in this paper and cite their sources.
Background Tyrosine kinase inhibitors (TKI) have been highlighted for the therapy of non-small-cell lung cancer (NSCLC), due to their capability of efficiently blocking signal pathway of epidermal growth factor receptor (EGFR) which causes the inhibition and apoptosis of NSCLC cells. However, EGFR-TKIs have poor aqueous solubility and severe side effects arising from the difficulty in control of biodistribution. In this study, folate-functionalized nanoparticles (FA-NPs) are designed and fabricated to load EGFR-TKI through flash nanoprecipitation (FNP) strategy, which could enhance the tumor-targeting drug delivery and reduced drug accumulation and side effects to normal tissues. Results Herein, the EGFR-TKI loaded FA-NPs are constructed by FNP, with FA decorated dextran- b -polylactide as polymeric stabilizer and gefitinib as TKI. The fast mixing and co-precipitation in FNP provide FA-NPs with well-defined particle size, narrow size distribution and high drug loading content. The FA-NPs exhibit efficient uptake and cytotoxicity in HCC827 NSCLC cells, and reduced uptake and cytotoxicity in normal cells comparing with free gefitinib. In vivo evaluation of gefitinib-loaded FA-NPs confirms the selective drug delivery and accumulation, leading to enhanced inhibition on NSCLC tumor and simultaneously diminished side effects to normal tissues. Conclusion The facile design of FA-NPs by FNP and their achieved performance in vitro and in vivo evaluations offer new therapeutic opportunities for treatment of non-small cell lung cancer.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: